Clinical Trial Update: Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating inhaled ultra-low doses of melphalan for non-cystic fibrosis bronchiectasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: Federal State Budgetary Institution, Pulmonology Scientific Research Institute | Conditions: Non-cystic Fibrosis Bronchiectasis | Phase 2 | Status: UNKNOWN